Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 537 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FDG Positron Emission Tomography Clear all
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 28, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

NCT05747625
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review
Biological · Drug · Procedure + 1 more
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Completed No phase listed Observational

PET Study in Patients With Non-Hodgkin Lymphoma

NCT00712556
View directory record Official record
Conditions
Lymphoma
Interventions
fluorine 18-fludeoxyglucose positron emission tomography
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

NCT02759887
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Dementia
Interventions
biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
Procedure · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

NCT03195777
View directory record Official record
Conditions
Deep Venous Thrombosis, Post-thrombotic Syndrome
Interventions
PET/CT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

NCT01283178
View directory record Official record
Conditions
Salivary Gland Squamous Cell Carcinoma, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
intensity-modulated radiation therapy, cisplatin, image-guided adaptive radiation therapy, 3'-deoxy-3'-[18F]fluorothymidine, positron emission tomography/computed tomography, fludeoxyglucose F 18
Radiation · Drug · Other + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

NCT05009979
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy
Drug · Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 28, 2026, 5:03 PM EDT
Not listed No phase listed Observational

FDG an Myocardial Infarction: The PIAF Trial

NCT05138718
View directory record Official record
Conditions
History of Myocardial Infarction
Interventions
18F-FDG PET/CT
Diagnostic Test
Lead sponsor
International Atomic Energy Agency
Government
Eligibility
18 Years to 80 Years
Enrollment
2,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 28, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

NCT01243359
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, bevacizumab, pharmacological study, laboratory biomarker analysis, fluorine F 18 fluorothymidine, positron emission tomography, computed tomography
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

NCT03432741
View directory record Official record
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

NCT00695305
View directory record Official record
Conditions
Atherosclerosis
Interventions
rilapladib, placebo, 18F Fluorodeoxylucose (FDG)-PET
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Haverhill, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
104
States / cities
Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 28, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Painful Post-Operative Hip Study

NCT07066709
View directory record Official record
Conditions
Unilateral Hip Arthroscopy
Interventions
FDG PET/MRI
Combination Product
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Imaging Mitochondrial Complex-I in Alcohol Use Disorder

NCT07825818
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Healthy Controls Group - Age and Sex-matched
Interventions
[F-18]BCPP-EF, [F-18]FDG
Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02390635
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions
Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI
Procedure · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

NCT02211768
View directory record Official record
Conditions
Neurofibromatosis, MPNST
Interventions
MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

NCT00581009
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
Other · Drug · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2011
U.S. locations
2
States / cities
Irvine, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Study of Temsirolimus, Topotecan, and Bortezomib

NCT00770731
View directory record Official record
Conditions
Advanced Cancer
Interventions
Torisel (Temsirolimus), Hycamtin (Topotecan), Velcade (Bortezomib)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 28, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer

NCT00039286
View directory record Official record
Conditions
Breast Cancer
Interventions
positron emission tomography, radionuclide imaging, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 28, 2026, 5:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

NCT01732640
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Afatinib, Paclitaxel, Carboplatin, Cisplatin, Intensity Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 28, 2026, 5:03 PM EDT